Compare YEXT & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YEXT | CABA |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 397.0M | 319.6M |
| IPO Year | 2017 | 2019 |
| Metric | YEXT | CABA |
|---|---|---|
| Price | $3.83 | $2.93 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $7.50 | ★ $14.50 |
| AVG Volume (30 Days) | 1.3M | ★ 3.5M |
| Earning Date | 06-02-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 131.82 | 10.26 |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $170,201,000.00 | N/A |
| Revenue This Year | $3.95 | N/A |
| Revenue Next Year | $2.46 | N/A |
| P/E Ratio | $198.25 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.27 | $1.26 |
| 52 Week High | $9.20 | $4.23 |
| Indicator | YEXT | CABA |
|---|---|---|
| Relative Strength Index (RSI) | 46.00 | 37.44 |
| Support Level | $3.66 | $2.11 |
| Resistance Level | $4.14 | $3.48 |
| Average True Range (ATR) | 0.24 | 0.26 |
| MACD | -0.00 | -0.07 |
| Stochastic Oscillator | 40.15 | 13.36 |
Yext Inc provides a knowledge engine platform that lets businesses manage their digital knowledge in the cloud and sync it to approximately 200 services including Apple Maps, Bing, Cortana, Facebook, Google, Google Maps, Instagram, Siri and Yelp. Digital knowledge is the structured information that a business wants to make publicly accessible. The company also makes search intelligent by helping to provide precise, accurate and current answers to location-based queries that are conducted across the web and mobile applications and voice and artificial intelligence, or AI, engines. The company derives the majority of its revenues from subscription services. Geographically, the company generates a majority of its revenue from North America and the rest from International markets.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.